Ammonium 2-amino-4-(hydroxymethylphosphinyl)butyrate

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

23 Sep. - 14 Oct. 1980

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

comparable to guideline study with acceptable restrictions

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1980

Report date:

1980

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

GLP compliance:

no

Remarks:

pre-GLP

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Ammonium 2-amino-4-(hydroxymethylphosphinyl)butyrate

EC Number:

278-636-5

EC Name:

Ammonium 2-amino-4-(hydroxymethylphosphinyl)butyrate

Cas Number:

77182-82-2

Molecular formula:

C5H12NO4P.H3N

IUPAC Name:

ammonium 2-amino-4-[hydroxy(methyl)phosphoryl]butanoate

Test animals

Species:

mouse

Strain:

NMRI

Remarks:

HoE: NMRKf (SPF71)

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Hoechst
- Weight at study initiation: 22 - 26 g
- Fasting period before study: not specified
- Housing: group
- Diet: produced by Altromin GmbH, ad libitum
- Water: tap water; ad libitum
- Acclimation period: not specified

ENVIRONMENTAL CONDITIONS
- Temperature (°C): not specified
- Humidity (%): not specified
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): not specified

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

water

Doses:

315, 500, 800 mg/kg bw

No. of animals per sex per dose:

10 (females only)

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: weighing weekly, observations of intoxication and mortality rate performed
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight

Statistics:

LD50 determined by probit analysis (Lindner/Weber method)
Confidence limits calculated: Fieller

Results and discussion

Effect levels

Sex:

female

Dose descriptor:

LD50

Effect level:

416 mg/kg bw

Based on:

act. ingr.

95% CL:

>= 345 - <= 498

Mortality:

1/10 animals / 315 mg/kg bw
8/10 animals / 500 mg/kg bw
10/10 animals / 800 mg/kg bw
Animals died within day 1 and 8 after treatment

Clinical signs:

Following symptoms were registered 24h after dosing: Ataxy, bizarre movements, squatting, abdominal position, clonic convulsions, convulsive jumping, rolling spasms, "Straub" phenomenon, increased salivation, irregular, jerky respiration, hyperactivity in the dosage group 315 mg/kg bw and benumbedness in the remaining groups.
Surviving animals recovered from day 2 after the treatment onwards whilst the animals that died later showed squatting, lateral posiion, bristled hair, poor general condition and in some instances barely perceptible respiratory movements which decreased respiratory rate until exitus

Body weight:

Before exitus marked decrease in body weight
Body weight gains of surviving animals were normal

Gross pathology:

Animals that died during the first days after the treatment showed translucent livers with hepatic marking at the edge in some instances and pulmonary plethora.
no abnormal findings for animals that died during the further course of the experiment or were killed after study termination